Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering

Rhea-AI Summary

Lixte Biotechnology (NASDAQ:LIXT) has successfully closed a $1.5 million registered direct offering with accredited investors. The offering comprised 974,026 shares of Common Stock (or Pre-Funded Warrants) at $1.54 per share ($1.53999 for Pre-Funded Warrants with a $0.00001 exercise price).

The transaction, which closed on July 8, 2025, was conducted under an effective shelf registration statement, with Spartan Capital Securities acting as the exclusive placement agent. The company plans to utilize the net proceeds for general corporate purposes and working capital, combining them with existing cash reserves.

Positive

• Secured $1.5 million in additional funding
• Pre-Funded Warrants are immediately exercisable
• Offering completed under effective shelf registration, indicating regulatory compliance

Negative

• Potential dilution for existing shareholders
• Relatively small offering size may indicate limited investor interest
• Low share price of $1.54 suggests challenging market conditions

Insights

Financial Analyst

Lixte raised $1.5M through share offering at $1.54, bolstering working capital but likely causing dilution for existing shareholders.

Lixte Biotechnology has completed a $1.5 million registered direct offering by selling 974,026 shares at $1.54 per share (or pre-funded warrants at effectively the same price). This capital raise is significant for a clinical-stage pharmaceutical company that needs consistent funding to advance its drug development programs.

The financing structure through a shelf registration (Form S-3) indicates the company had anticipated capital needs and positioned itself to raise funds efficiently when required. This approach typically allows faster execution compared to other financing methods.

The share price of $1.54 in this offering provides a reference point for how the market currently values the company. With 974,026 new shares being issued, existing shareholders will experience a dilution effect, as their percentage ownership in the company decreases proportionally.

The stated use of proceeds for "general corporate purposes and working capital" suggests this funding is primarily aimed at extending the company's operational runway rather than for a specific strategic initiative or clinical trial. For clinical-stage biotech companies like Lixte, maintaining sufficient working capital is critical, as they typically generate minimal or no revenue while incurring significant R&D expenses.

The involvement of Spartan Capital Securities as the exclusive placement agent indicates this was a carefully coordinated offering to select accredited investors rather than a broader public offering, which is a common approach for smaller biotech fundraising events.

PASADENA, CALIF, July 08, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a registered direct offering with accredited investors for the purchase and sale of approximately $1.5 million of shares of Common Stock (or Pre-Funded Warrants).

The offering consisted of the sale of an aggregate of 974,026 shares of Common Stock (or Pre-funded Warrants in lieu thereof). The public offering price per share of Common Stock was $1.54 (or $1.53999 for each Pre-Funded Warrant, which is equal to the offering price per share of Common Stock sold in the offering minus an exercise price of $0.00001). The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full.

Aggregate gross proceeds to the Company were approximately $1.5 million. The transaction closed on July 8, 2025. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.

Spartan Capital Securities, LLC acted as exclusive placement agent for the offering. TroyGould PC acted as counsel to the Company. Kaufman & Canoles, P.C. acted as counsel to Spartan Capital Securities, LLC.

The registered direct offering was made pursuant to an effective shelf registration statement on Form S-3 (No. 333-278874) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on May 2, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Spartan Capital Securities, LLC, Attention: Prospectus Department, 45 Broadway, 19th Floor, New York, NY 10006, by e-mail at investmentbanking@spartancapital.com. Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.

LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at www.lixte.com.

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962

FAQ

What is the size and price of LIXT's July 2025 registered direct offering?

Lixte Biotechnology raised $1.5 million through the sale of 974,026 shares at $1.54 per share (or Pre-Funded Warrants at $1.53999).

How will LIXT use the proceeds from the July 2025 offering?

The company plans to use the net proceeds, combined with existing cash, for general corporate purposes and working capital.

Who was the placement agent for LIXT's July 2025 offering?

Spartan Capital Securities, LLC acted as the exclusive placement agent for the offering.

What are the terms of LIXT's Pre-Funded Warrants from the July 2025 offering?

The Pre-Funded Warrants are priced at $1.53999 with an exercise price of $0.00001 and are immediately exercisable until fully exercised.

When did LIXT's shelf registration statement become effective?

Lixte's shelf registration statement on Form S-3 (No. 333-278874) was declared effective by the SEC on May 2, 2024.